VRDN Viridian Therapeutics Inc

USD 13.51 -0.25 ( -1.82%)
Icon

Viridian Therapeutics Inc (VRDN) Financial Statements

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 13.51

-0.25 (-1.82%)

USD 0.98B

0.63M

USD 38.81(+187.29%)

N/A

Icon

VRDN

Viridian Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 13.51
-0.25 ( -1.82%)

Viridian Therapeutics Inc (VRDN) Annual Income Statement (USD)

VRDN Quarterly Financials (USD)

Frequently Asked Questions About Viridian Therapeutics Inc (VRDN) Stock

Viridian Therapeutics Inc's (VRDN) last reported annual revenue was USD 302000.00.

Viridian Therapeutics Inc's (VRDN) annual revenue growth rate based on the revenue reported in the past 5 years is : -41.64%

Viridian Therapeutics Inc's(VRDN) is not profitable as of its last reported annual financials.

The net profit margin for Viridian Therapeutics Inc's(VRDN) from its laster reported year is -89387.09%

The return on equity (ROE) for Viridian Therapeutics Inc's(VRDN) from its last reported annual financials is : -48.48%

The return on assets (ROA) for Viridian Therapeutics Inc's(VRDN) from its last reported annual financials is : -30.32%

The return on invested capital (ROIC) for Viridian Therapeutics Inc's(VRDN) from its last reported annual financials is : -5.04%

The Debt to Equity ratio for Viridian Therapeutics Inc's(VRDN) from its last reported annual financials is : 3.06%

The dividend yield for Viridian Therapeutics Inc's(VRDN) from its laster reported year is 0.00%

Viridian Therapeutics Inc's(VRDN) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...